Multiple roles of FGF10 in the regulation of corneal endothelial wound healing

Corneal endothelial dysfunction usually induces corneal haze and oedema, which seriously affect visual function. The main therapeutic strategy for this condition is corneal transplantation, but the use of this strategy is limited by the shortage of healthy donor corneas. Compared with corneal transplantation, drug intervention is less invasive and more accessible; thus, finding an effective pharmaceutical alternative for cornea transplantation is critical for the treatment of corneal endothelial dysfunction. In this study, we established a rabbit scratch model to investigate the effect of fibroblast growth factor 10 (FGF10) on corneal endothelial wound healing. Results showed that FGF10 injection accelerated the recovery of corneal transparency and increased the protein expression levels of ZO1, Na + /K + -ATPase and AQP-1. Moreover, FGF10 significantly inhibited the expression levels of endothelial-to-mesenchymal transition proteins and reduced the expression levels of the proinflammatory factors IL-1β and TNF-α in the anterior chamber aqueous humour. FGF10 also enhanced the Na + /K + -ATPase activity by enhancing mitochondrial function as a result of its direct interaction with its conjugate receptor. Thus, FGF10 could be a new pharmaceutical preparation as treatment for corneal endothelial dysfunction. • This study focused on the roles of Fibroblast growth factor 10 (FGF10) on corneal endothelium and whether FGF10 can promote corneal endothelial repair. And the results showed that FGF10 injection accelerated the recovery of corneal transparency and promoted the protein expressions of ZO1, Na + /K + -ATPase, and AQP-1. In addition, FGF10 significantly inhibited the protein expressions of the endothelial-to-mesenchymal transition (EnMT) markers and reduced the expression levels of the proinflammatory factors IL-1β, TNF-α in the anterior chamber aqueous humour. FGF10 also enhanced the Na + /K + -ATPase activity by enhancing mitochondrial function as a result of its direct interaction with its conjugate receptor. Thus, FGF10 could be a new pharmaceutical preparation as treatment for corneal endothelial dysfunction.